Is Retatrutide a GLP-1 Drug or a “GLP-3”?
Short answer: Retatrutide activates the GLP-1 receptor, but it is not a GLP-1 single agonist. It simultaneously activates three receptors: GIP, GLP-1, and glucagon. “GLP-3” is an informal nickname with no scientific basis — it does not correspond to any real receptor, hormone, or drug class recognized in pharmacology or peer-reviewed literature.
Key Facts
Where Did “GLP-3” Come From?
The nickname “GLP-3” appears to have originated in online communities — primarily Reddit, fitness forums, and social media — as a shorthand for drugs that activate more receptors than GLP-1 single agonists like semaglutide. The logic was informal: if semaglutide is “GLP-1” and tirzepatide is “GLP-2” (dual), then a triple agonist must be “GLP-3.”
This reasoning is incorrect on multiple levels. GLP-2 is an actual, separate hormone (glucagon-like peptide-2) with its own receptor, unrelated to tirzepatide. Tirzepatide is a GIP/GLP-1 dual agonist, not a “GLP-2” drug. And “GLP-3” does not correspond to any hormone, receptor, or drug class in pharmacology.
No peer-reviewed publication, FDA filing, or Eli Lilly communication uses the term “GLP-3” to describe retatrutide.
What Retatrutide Actually Is: A Triple Receptor Agonist
Retatrutide (LY3437943) is a single investigational molecule that simultaneously activates three distinct receptors:
| Receptor | Primary metabolic effect | Also activated by |
|---|---|---|
| GLP-1 receptor | Reduces appetite, slows gastric emptying, lowers blood glucose | Semaglutide, tirzepatide, liraglutide |
| GIP receptor | Enhances insulin secretion, may reduce GI side effects of GLP-1 activation | Tirzepatide |
| Glucagon receptor | Increases energy expenditure, promotes lipolysis (fat breakdown) | No approved obesity drug as of 2026 |
The glucagon receptor component is what distinguishes retatrutide from tirzepatide. For a deeper explanation of the mechanism, see How Retatrutide Works.
How Retatrutide Compares to Other Drug Classes
| Drug | Class | Receptors | FDA status |
|---|---|---|---|
| Semaglutide (Ozempic/Wegovy) | GLP-1 single agonist | GLP-1 | FDA-approved |
| Liraglutide (Saxenda) | GLP-1 single agonist | GLP-1 | FDA-approved |
| Tirzepatide (Mounjaro/Zepbound) | GIP/GLP-1 dual agonist | GIP + GLP-1 | FDA-approved |
| Retatrutide (LY3437943) | Triple receptor agonist | GIP + GLP-1 + glucagon | Investigational — not approved |
Why Terminology Matters
Using accurate terminology matters for regulatory discussions, safety conversations, and avoiding misinformation. Retatrutide is not simply a “stronger” version of semaglutide — it is a mechanistically distinct investigational compound with a different receptor profile and an unapproved status.
For a comparison of retatrutide and semaglutide using clinical data, see Retatrutide vs Semaglutide. For the tirzepatide comparison, see Retatrutide vs Tirzepatide.
Retatrutide is not FDA-approved and is not available by prescription. It cannot be legally compounded by 503A pharmacies or 503B outsourcing facilities under current federal law. It is available only to participants enrolled in authorized clinical trials. TryTrutide does not sell, prescribe, compound, or dispense retatrutide.
Frequently Asked Questions
Is retatrutide a GLP-1 drug?
Yes — retatrutide activates the GLP-1 receptor, among others. It is more precisely described as a triple receptor agonist (GIP, GLP-1, and glucagon), not a GLP-1 single agonist like semaglutide.
What does "GLP-3" mean?
"GLP-3" is an informal nickname with no scientific basis. There is no receptor or hormone formally designated GLP-3 in pharmacology. The term has circulated online as shorthand for triple agonists but is scientifically inaccurate and not used in peer-reviewed literature.
How is retatrutide different from semaglutide?
Semaglutide activates only the GLP-1 receptor. Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors. This triple mechanism is hypothesized to produce greater metabolic effects, and Phase 2 data showed substantially greater weight loss (~24% vs ~15%), though no direct head-to-head trial exists.
How is retatrutide different from tirzepatide?
Tirzepatide (Mounjaro/Zepbound) is a dual agonist activating GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activation, making it a triple agonist. The additional glucagon component is thought to further increase energy expenditure.
Is "triple agonist" the correct term?
Yes. "Triple receptor agonist," "triple agonist," or "GIP/GLP-1/glucagon receptor agonist" are all scientifically accurate. Retatrutide's INN and clinical literature use these terms. "GLP-3" is not used in any peer-reviewed publication.
Does the glucagon component cause problems?
Glucagon receptor activation raises blood glucose in isolation, which initially raised safety questions. In the context of retatrutide's combined GLP-1 and GIP activity, the net effect in Phase 2 trials was glucose-lowering, not glucose-raising. The glucagon component is thought to primarily increase energy expenditure and lipolysis.